NSE: CAPLIPOINT | BSE: 524742

Mid-range Performer

Download real time

2325.60 -50.50 (-2.13%)

55.01% Gain from 52W Low

134.0K NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

17,677.3

Market Cap

High in industry

Beta 1Year

Very Low volatility

Caplin Point Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CAPLIPOINT, BSE:524742 Caplin Point Laboratories Ltd.

Search Inside the pdf :

Caplin Point Laboratories Ltd.

15 May 2026

2325.60

-2.13%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Direct

Caplin Steriles caters mainly to the US and other regulated markets. So far, it has developed and filed 65 ANDAs in the US on its own and with partners, with 59 approvals as on date. The Company is also working on a portfolio of 55+ simple and complex Injectable and Ophthalmic products,...

Caplin Point Labs has gained 36.08% in the last 6 Months

Caplin Point Laboratories Ltd.

06 Feb 2026

2325.60

-2.13%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Direct

Caplin Steriles caters mainly to the US and other regulated markets. So far, it has developed and filed 52 ANDAs in the US on its own and with partners, with 42 approvals as on date. The Company is also working on a portfolio of 40+ simple and complex Injectable and Ophthalmic products,...

Number of FII/FPI investors increased from 185 to 203 in Sep 2026 qtr.

Caplin Point Laboratories Ltd.

10 Nov 2025

2325.60

-2.13%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Direct

Firm expansion plans in place- In the US, the company is optically transitioning to B2C model to focus on high margin products. The company is also looking for third party ANDAs (4 already acquired, 5 more to come) as well as outsourcing some in-house products to the CMOs for optimal plant utilisation. This, we believe is a part of larger strategy where the company wants to increase the offerings via front-end and at the same time focusing on margin expansion. The legacy LatAm growth was slower seemingly on account of some saturation in the existing markets and focus...

Number of FII/FPI investors increased from 185 to 203 in Sep 2026 qtr.

Caplin Point Laboratories Ltd.

14 Aug 2025

2325.60

-2.13%

Be Unique. Go Big.

Buy: Caplin Point Laboratories ...

FundsIndia

Number of FII/FPI investors increased from 185 to 203 in Sep 2026 qtr.

Caplin Point Laboratories Ltd.

11 Nov 2024

2325.60

-2.13%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Direct

Caplin Point Laborat.. has an average target of 2320.00 from 1 broker.

Caplin Point Laboratories Ltd.

08 Aug 2024

2325.60

-2.13%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Direct

Caplin Point Laboratories Ltd. is trading below its 30 day SMA of 2521.0

Caplin Point Laboratories Ltd.

25 Apr 2024

2325.60

-2.13%

Next Phase of Strategic Growth

Accumulate: Caplin Point Laboratories ...

Asit C Mehta Investment Interrmediates

CAPLIPOINT has transformed itself into a player in generic formulations with a
differentiated geographical presence. The company focuses on the emerging
markets of LATAM and has taken an early-mover advantage in these largely
untapped markets